- Home
- SMSI vs BIAF Comparison
SMSI vs BIAF Comparison
Compare SMSI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- BIAF
- Stock Information
- Founded
- SMSI 1982
- BIAF 2014
- Country
- SMSI United States
- BIAF United States
- Employees
- SMSI N/A
- BIAF N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SMSI Technology
- BIAF Health Care
- Exchange
- SMSI Nasdaq
- BIAF Nasdaq
- Market Cap
- SMSI 16.2M
- BIAF 14.5M
- IPO Year
- SMSI 1995
- BIAF 2022
- Fundamental
- Price
- SMSI $1.13
- BIAF $0.68
- Analyst Decision
- SMSI Strong Buy
- BIAF Strong Buy
- Analyst Count
- SMSI 1
- BIAF 1
- Target Price
- SMSI $5.00
- BIAF $6.00
- AVG Volume (30 Days)
- SMSI 732.1K
- BIAF 313.4K
- Earning Date
- SMSI 02-20-2025
- BIAF 11-14-2024
- Dividend Yield
- SMSI N/A
- BIAF N/A
- EPS Growth
- SMSI N/A
- BIAF N/A
- EPS
- SMSI N/A
- BIAF N/A
- Revenue
- SMSI $24,178,000.00
- BIAF $9,367,785.00
- Revenue This Year
- SMSI N/A
- BIAF $285.51
- Revenue Next Year
- SMSI $53.43
- BIAF $20.05
- P/E Ratio
- SMSI N/A
- BIAF N/A
- Revenue Growth
- SMSI N/A
- BIAF 2813.87
- 52 Week Low
- SMSI $0.52
- BIAF $0.66
- 52 Week High
- SMSI $7.52
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- SMSI 47.52
- BIAF 26.89
- Support Level
- SMSI $1.05
- BIAF $0.67
- Resistance Level
- SMSI $1.95
- BIAF $1.01
- Average True Range (ATR)
- SMSI 0.23
- BIAF 0.08
- MACD
- SMSI -0.06
- BIAF -0.01
- Stochastic Oscillator
- SMSI 8.89
- BIAF 4.29
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.